Xtant Medical Updates Q1 Results and Raises 2026 Guidance

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Xtant Medical Holdings ( (XTNT) ) has shared an update. On May 13, 2026, Xtant Medical reported first-quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, as it continued to feel the impact of selling its Coflex/CoFix assets and international hardware business to Companion Spine in December 2025 and the non-recurrence of prior license revenue. The company posted a net loss of $3.1 million versus a small profit a year earlier, but reduced total indebtedness by $13.3 million, improved liquidity, and raised its full-year 2026 revenue guidance to $101–$105 million on the back of a new U.S. hemostasis product distribution deal. Xtant strengthened its balance sheet by using Companion Spine sale proceeds to pay down its term loan and revolving credit facility, while also finalizing a total $21.4 million cash purchase price in March 2026. Strategically, it broadened its portfolio and sales reach by securing exclusive U.S. rights to Dilon Technologies’ HEMOBLAST Bellows hemostatic product, hiring Dilon’s roughly 20-person U.S. sales team, and launching Trivium Shaped allograft, moves that expand its addressable markets and aim to support future topline growth and margin expansion. Separately, the company set August 7, 2026 as the date of its 2026 annual meeting of stockholders and outlined new deadlines for shareholder proposals and director nominations following the shift of more than 30 days from last year’s meeting date. Investors and activists seeking to submit proposals or nominate directors must meet accelerated May and June 2026 notification timelines and comply with both Xtant’s bylaws and U.S. proxy rules, including universal proxy requirements. The most recent analyst rating on (XTNT) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page. Spark’s Take on XTNT Stock According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral. XTNT scores as a moderate-risk turnaround: financial performance is improving with positive earnings and cash flow and reduced leverage, but sustainability is still being proven. The technical setup is weak (below major moving averages with negative MACD), while earnings-call guidance points to a near-term reported revenue decline despite better profitability and cash flow focus; valuation is middling with no dividend support. To see Spark’s full report on XTNT stock, click here. More about Xtant Medical Holdings Xtant Medical Holdings, Inc. is a global medical technology company focused on designing, developing, and commercializing a comprehensive portfolio of orthobiologics for chronic and surgical wound care and sports medicine, as well as spinal implant systems. The company targets surgeons and patients needing advanced biologics and hardware solutions for spinal and other orthopedic conditions. Average Trading Volume: 143,207 Technical Sentiment Signal: Sell Current Market Cap: $70.65M